Catalyst Crew Technologies Corp. (OTC: CCTC) announced today that it has assigned three Venezuelan patents to its wholly-owned subsidiary, Inversiones Long 33, C.A. The patents, previously held by CEO Dr. Kevin Rodan Levy, cover proprietary technologies CardioAI, PulmoAI, and NeuroAI, which are designed for data-driven healthcare analytics, predictive modeling, and clinical decision-support applications.
This assignment consolidates the company’s intellectual property at the operating level, a move that management believes will enhance strategic flexibility and support regulatory alignment. The company stated that the subsidiary is now positioned as the primary development and commercialization vehicle for its technology platform in the region, potentially facilitating future partnerships, licensing opportunities, and regional expansion initiatives.
In addition to the patent assignment, Catalyst Crew Technologies intends to pursue expanded intellectual property protection for its technologies in additional jurisdictions worldwide. This global IP strategy is aimed at supporting long-term platform development and potential international deployment of its digital health solutions.
Dr. Kevin Rodan Levy, Chief Executive Officer, commented: “Aligning our intellectual property within our operating structure is an important step as we continue building our platform. Establishing a clear foundation around our core technologies allows us to move forward with development, partnerships, and, where appropriate, broader intellectual property protection strategies across additional markets.”
The company continues to advance its digital health and artificial intelligence platform, focusing on scalable healthcare solutions such as telehealth infrastructure, remote patient monitoring, and advanced healthcare analytics. These technologies are designed to improve access, efficiency, and care coordination in emerging markets, with an initial emphasis on Latin America.
Catalyst Crew Technologies Corp. is an AI-driven healthcare technology company actively executing a strategic transition into AI-enabled healthcare. Through technology development, strategic partnerships, and targeted acquisitions, the company is building an integrated healthcare technology platform to address the growing demand for modernized healthcare delivery systems across emerging markets.
For more information, visit https://catalystcrewai.com or review the company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
